Rothschild & Co. Asset Management US Inc. boosted its position in BioScrip Inc (NASDAQ:BIOS) by 82.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,174,826 shares of the company’s stock after purchasing an additional 985,235 shares during the quarter. Rothschild & Co. Asset Management US Inc. owned approximately 1.70% of BioScrip worth $6,742,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. raised its holdings in BioScrip by 0.4% in the third quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock worth $23,610,000 after purchasing an additional 31,899 shares in the last quarter. FMR LLC increased its holdings in shares of BioScrip by 3.3% during the second quarter. FMR LLC now owns 5,593,200 shares of the company’s stock valued at $16,388,000 after acquiring an additional 179,700 shares in the last quarter. Millennium Management LLC increased its holdings in shares of BioScrip by 10.6% during the second quarter. Millennium Management LLC now owns 2,682,984 shares of the company’s stock valued at $7,861,000 after acquiring an additional 257,202 shares in the last quarter. Royce & Associates LP increased its holdings in shares of BioScrip by 6.6% during the second quarter. Royce & Associates LP now owns 2,127,000 shares of the company’s stock valued at $6,232,000 after acquiring an additional 132,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of BioScrip by 43.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,962,506 shares of the company’s stock valued at $5,750,000 after acquiring an additional 597,847 shares in the last quarter. Institutional investors and hedge funds own 85.39% of the company’s stock.
Several brokerages have recently weighed in on BIOS. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a report on Wednesday. TheStreet upgraded BioScrip from a “d+” rating to a “c-” rating in a report on Monday. Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Barrington Research restated a “buy” rating and set a $4.00 price target on shares of BioScrip in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. BioScrip has a consensus rating of “Buy” and an average price target of $3.56.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $181.00 million during the quarter, compared to the consensus estimate of $171.35 million. During the same period last year, the firm earned ($0.12) EPS. The business’s quarterly revenue was down 8.9% compared to the same quarter last year. On average, sell-side analysts anticipate that BioScrip Inc will post -0.33 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Rothschild & Co. Asset Management US Inc. Boosts Holdings in BioScrip Inc (BIOS)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/11/30/rothschild-co-asset-management-us-inc-boosts-holdings-in-bioscrip-inc-bios.html.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.